Addressing the disparities: the approach to the African American patient with multiple myeloma
- PMID: 38110338
- PMCID: PMC10728116
- DOI: 10.1038/s41408-023-00961-0
Addressing the disparities: the approach to the African American patient with multiple myeloma
Abstract
There are significant disparities with regards to incidence, timely diagnosis, access to treatment, clinical trial participation and health care utilization that negatively impact outcomes for African American patients with multiple myeloma. Health care providers have a role in ameliorating these disparities with thoughtful consideration of historical, sociocultural, individual and disease characteristics that influence the care provided to African American patient population. This review by a group of experts committed to health disparity in multiple myeloma provides a snapshot of disparities at both biologic and non-biologic levels, barriers to clinical care, and best practices to ensure that African American patients receive the best care available.
© 2023. The Author(s).
Conflict of interest statement
MB has received institutional research support for clinical trials from Janssen, BMS/Celgene, Amgen, Adaptive Biotechnologies, MedImmune, Celularity, Millenium, and Takeda. BJB has served as a consultant for Janssen, Sanofi, Pfizer, Abbvie, and Oncopeptides. CC has received research funding from GSK; and served as a consultant for Abbvie, Genentech, Janssen, Pfizer, Sanofi, AstraZeneca. AZB has received research funding from Janssen, BMS, Roche, and GSK. SZU has received research funding from Abbvie, Amgen, Array Biopharma, BMS, Celgene, GSK, Gilead, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; and served as a consultant for Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Novartis, Merck, Moderna, Oncopeptides, Pfizer, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio. AKN has received grant funding and personal fees from GSK, Janssen, Bristol-Myers Squibb, Takeda, Pfizer, Karyopharm, and Amgen; and has received personal fees from Beyond Springs, Adaptive, SecuraBio, Sanofi, and Oncopeptides. LB-M: Employment: Kodikas Therapeutic Solutions, Takeda Science Foundation; Stock and Other Ownership Interests: Kodikas Therapeutic Solutions; Honoraria: Celgene; Consulting or Advisory Role: Celgene; Research Funding: Takeda; Patents, Royalties, Other Intellectual Property: We have discovered that translocation of NFKB2 predicts response to proteasome inhibitors. Test has been patented and licensed to Empire Genomics; Travel, Accommodations, Expenses: Celgene. JM has served as a consultant for Amgen, BMS, Janssen, Sanofi, and Taked.
References
-
- Harris DR, Andrews R, Elixhauser A. Racial and gender differences in use of procedures for black and white hospitalized adults. Ethn Dis. 1997;7:91–105. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
